Modality
Nanobody
MOA
BTKi
Target
CD20
Pathway
Checkpoint
RA
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
~Mar 2018
→ ~Jun 2019
NDA/BLA
Sep 2019
→ Jan 2030
NDA/BLACurrent
NCT05393117
251 pts·RA
2019-09→2026-02·Completed
NCT04604168
1,322 pts·RA
2025-08→2030-01·Active
1,573 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-141mo agoPh3 Readout· RA
2030-01-113.8y awayPh3 Readout· RA
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
NDA/BLA
Complet…
NDA/BLA
Active
Catalysts
Ph3 Readout
2026-02-14 · 1mo ago
RA
Ph3 Readout
2030-01-11 · 3.8y away
RA
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05393117 | NDA/BLA | RA | Completed | 251 | Biomarker |
| NCT04604168 | NDA/BLA | RA | Active | 1322 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN |